NovoCure Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
NovoCure has a total shareholder equity of $360.8M and total debt of $654.5M, which brings its debt-to-equity ratio to 181.4%. Its total assets and total liabilities are $1.2B and $861.2M respectively.
Belangrijke informatie
181.4%
Verhouding schuld/eigen vermogen
US$654.48m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$959.90m |
| Aandelen | US$360.78m |
| Totaal verplichtingen | US$861.21m |
| Totaal activa | US$1.22b |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: N2VC34's short term assets ($1.1B) exceed its short term liabilities ($735.0M).
Langlopende schulden: N2VC34's short term assets ($1.1B) exceed its long term liabilities ($126.2M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: N2VC34 has more cash than its total debt.
Schuld verminderen: N2VC34's debt to equity ratio has increased from 78.5% to 181.4% over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: N2VC34 has sufficient cash runway for more than 3 years based on its current free cash flow.
Voorspelling contante baan: Insufficient data to determine if N2VC34 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.